Renowned experts discuss new approaches to cancer therapy at international conference

NewsGuard 100/100 Score

An international conference attended by more than 70 of the world's leading experts and investigators in the field of Ephs and ephrins was held locally this week and hosted by Waldemar Debinski, M.D., Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest University Baptist Medical Center.

The bi-annual conference focused on the biggest known family of protein tyrosine kinase proteins, termed Ephs and ephrins, which are involved in various processes of brain development and blood vessel organization. They significantly contribute to tumor progression and maintenance in adult life, but Debinski and his colleagues believe that by molecularly targeting Ephs and ephrins, they will be able to bring novel approaches to cancer therapy, including brain tumors.

"Ephs and ephrins are also of paramount importance in development, especially of the central nervous system, and pathophysiology/biology of multiple human disorders," Debinski said. "Our meeting is unique in that it brings cancer researchers together with investigators studying development or other physiological processes. I believe this provides a fertile ground for learning from one another in order to resolve basic problems and to explore potential novel medical interventions targeting Ephs and ephrins."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases